Furthermore, the acquisition of a FLT3 mutation is associated with inferior outcomes: a retrospective review of 3555 AML patients at MD Anderson Cancer Center showed that the acquisition of a FLT3 mutation during the course of the disease correlated strongly with disease progression and poor prognosis [67]. The gene discussed is FLT3; the disease is acute myeloid leukemia.